The Japanese T2D study for evaluating Benefits Of a New first-line therapy with Dapagliflozin in consideration of improving QOL (J-BOND study)
- Conditions
- type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000030514
- Lead Sponsor
- the Japan Society for Patient Reported Outcome (PRO)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 252
Not provided
Patients who fall into any of the following criteria are excluded from participating in the study: 1.Patients with any experience of using any antidiabetic medication within last three months 2.Patients with medical history of severe hypoglycemia within a year 3.Patients with type 1 diabetes mellitus or secondary diabetes 4.Patients during a perioperative period, or patients with severe infection or severe physical injury 5.Patients with moderate to severe heart failure (NYHA/New York Heart Association at class III or higher) 6.Patients with moderate renal disease (eGFR < 45mL/min/1.73 m2) 7.Patients with severe liver disease (AST 100 IU/l or higher) 8.Patients who are addicted to alcohol or a drug 9.Patients who are breastfeeding, pregnant, possibly pregnant, or planning to be pregnant 10.Patients with dementia 11.Patients with a contraindicated condition to use the study drug 12.Patients with other conditions that the investigator/researcher thinks inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method